Inovio Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Inovio Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
Inovio Pharmaceuticals: 28 sponsored US clinical trials, none currently recruiting.
Inovio Pharmaceuticals sponsors 28 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 24 completed. 6 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HSIL, with 2 trials.
Top-decile sponsor footprint
Inovio Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
24 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
28 total, page 1 of 1
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
NCT03491683
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
NCT04642638
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
NCT04398433
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
NCT04336410
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
NCT03805984
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03721978
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
NCT03502785
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
NCT03499795
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
NCT03180684
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03185013
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
NCT02514213
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
NCT02464670
Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
NCT02431312
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
NCT02960594
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
NCT02163057
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
NCT02172911
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
NCT02241369
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
NCT01405885
A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
NCT01403155
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
NCT01304524
Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
NCT01082692
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
NCT01188850
Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults
NCT01142362
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
NCT00685412
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
NCT00198328
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
NCT00198315
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
NCT00198276
Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
NCT00198263
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Therapeutic Areas
How the Inovio Pharmaceuticals early-phase archive is shaped
28 indexed studies, none listed as recruiting (0% open); 24 completed (86%).
Phase mix: 6 late (III/IV) vs 22 early (I/II) (early-phase heavy).
Top condition: HSIL (2 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Inovio Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 28 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Inovio Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 archived trials
- Axsome Therapeutics · 28 trials · 21% recruiting
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- CTI BioPharma · 28 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Inovio Pharmaceuticals page
28 registered trials is a research-attention snapshot, not an endorsement of Inovio Pharmaceuticals or any single study.
- None of Inovio Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- HSIL is the condition Inovio Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HSIL trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Inovio Pharmaceuticals pipeline card: 28 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.